POAG puts pressure on the heart

Article

Patients with primary open-angle glaucoma (POAG) have a higher level of cardiovascular risk than in age-matched patients without glaucoma, according to a report published in a recent issue of Graefe's Archive for Clinical and Experimental Ophthalmology.

Patients with primary open-angle glaucoma (POAG) have a higher level of cardiovascular risk than in age-matched patients without glaucoma, according to a report published in a recent issue of Graefe's Archive for Clinical and Experimental Ophthalmology.

Nicola Orzalesi and colleagues from the OPTIME Study group, collected and analysed data from the medical history of 2,879 POAG patients and 973 age-matched controls, from 35 centres in Italy. Data relating to vascular risk factors were collected by means of a detailed questionnaire and all subjects underwent a complete ophthalmic examination with assessment of intraocular pressure (IOP), visual field, optic disc and systemic blood pressure. The European Society of Hypertension/European Society of Cardiology (ESH-ESC) guidelines were used to calculate the level of cardiovascular risk.

The POAG patients had significantly higher systolic and diastolic blood pressure, systolic perfusion pressure and IOP compared to the control group. However, diastolic perfusion pressure did not significantly differ between the groups. Myopia was more common in the POAG group (23% compared to 18%), as was a positive family history of glaucoma (26% compared to 12%). POAG patients also tended to have a higher cardiovascular risk than controls. A total of 63% of POAG patients and 55% of controls had a high or very high cardiovascular risk.

The authors found that patients with POAG do have a greater cardiovascular risk than those who do not have glaucoma.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
Related Content
© 2024 MJH Life Sciences

All rights reserved.